This SPA proposed to amend the maximum allowable cost for selected multi-source brand and generic drugs to range from average wholesale price (A WP) minus 72 percent to step down tiers through A WP minus 20 percent based on meeting specific invoice pricing criteria.
State
Topics
Approval Date
Effective Date
File 1 - Approval Document Media